Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07284758 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
A Phase 2 study of Multiple Myeloma and Relapsed/Refractory Multiple Myeloma, sponsored by C4 Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 3
- Study locations
NCT07284758 is a Phase 2 study of Multiple Myeloma and Relapsed/Refractory Multiple Myeloma that is actively recruiting participants, run by C4 Therapeutics. The registered enrollment target is 100 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (82% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT07284758, a Phase 2 study of Multiple Myeloma and Relapsed/Refractory Multiple Myeloma, is actively recruiting participants, sponsored by C4 Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a Phase 2, open-label, single-arm, multicenter study to assess the antimyeloma activity and further characterize the safety, tolerability, PK, and PD of cemsidomide in combination with dexamethasone in participants with relapsed/refractory multiple myeloma (r/r MM).
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Cemsidomide
Study Locations (3)
California
- Berenson Cancer Center - West Hollywood
Michigan
- START Midwest - Grand Rapids
Texas
- START San Antonio - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2026-02-18 |
| Est. Completion | 2030-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07284758
The ClinicalTrials.gov registry entry for NCT07284758 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (82% lower). The listed sponsor is C4 Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Dexamethasone is the first listed.
NCT07284758 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Michigan, Texas.
Frequently Asked Questions
What is clinical trial NCT07284758 about?
NCT07284758 is a clinical study titled "A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma". This is a Phase 2, open-label, single-arm, multicenter study to assess the antimyeloma activity and further characterize the safety, tolerability, PK, and PD of cemsidomide in combination with dexamethasone in participants with relapsed/refractory multiple myeloma (r/r MM).
What is the current status of trial NCT07284758?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2026-02-18. Estimated completion is 2030-03.
What conditions does trial NCT07284758 study?
This clinical trial studies the following conditions: Multiple Myeloma, Relapsed/Refractory Multiple Myeloma.
What interventions are being tested in trial NCT07284758?
The interventions under investigation include: Dexamethasone (DRUG), Cemsidomide (DRUG).
Who is sponsoring clinical trial NCT07284758?
This trial is sponsored by C4 Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07284758 being conducted?
This trial has 3 study locations across California, Michigan, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.